| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11899-009-0011-8 |
| P698 | PubMed publication ID | 20425418 |
| P50 | author | Muriel Malaise | Q75192311 |
| P2093 | author name string | Daniel Steinbach | |
| Selim Corbacioglu | |||
| P2860 | cites work | Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 |
| Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | Q24299873 | ||
| Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia | Q27851423 | ||
| TOR signaling in growth and metabolism | Q27860757 | ||
| Rapamycins: mechanism of action and cellular resistance | Q28189252 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Cancer-susceptibility genes. Gatekeepers and caretakers | Q28236512 | ||
| Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
| Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model | Q28590872 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. | Q33186348 | ||
| Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump | Q33204719 | ||
| ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? | Q33281867 | ||
| RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia | Q33306326 | ||
| AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. | Q33762738 | ||
| Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study | Q34570206 | ||
| Genetics of myeloid leukemias | Q34795893 | ||
| Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | Q35751042 | ||
| Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs | Q36854122 | ||
| Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia | Q37198180 | ||
| Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration | Q38291182 | ||
| A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors | Q38304282 | ||
| Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations. A report of three cases | Q38330251 | ||
| A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease | Q39218023 | ||
| In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. | Q39966280 | ||
| Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia | Q39981814 | ||
| Initial testing of dasatinib by the pediatric preclinical testing program | Q40072248 | ||
| Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin | Q40255904 | ||
| KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival | Q40357255 | ||
| Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia | Q40405651 | ||
| A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. | Q40455631 | ||
| Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations | Q42742043 | ||
| SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes | Q44370169 | ||
| Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable | Q44443469 | ||
| Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders | Q44454011 | ||
| Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571). | Q44548391 | ||
| Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia | Q44730502 | ||
| Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia | Q44906435 | ||
| PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways | Q45259661 | ||
| Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. | Q46525334 | ||
| Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. | Q46558722 | ||
| PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects | Q46724516 | ||
| KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group | Q46807536 | ||
| Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell | Q46815322 | ||
| Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. | Q46824584 | ||
| Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies | Q46882720 | ||
| Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas | Q46900234 | ||
| Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. | Q46957156 | ||
| Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib | Q47811823 | ||
| Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). | Q52569827 | ||
| c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia | Q59511748 | ||
| Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells | Q67704489 | ||
| C-kit mutations in core binding factor leukemias | Q73413358 | ||
| P433 | issue | 2 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 77-82 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | Current hematologic malignancy reports | Q26842233 |
| P1476 | title | Clinical implications of c-Kit mutations in acute myelogenous leukemia | |
| P478 | volume | 4 |
| Q34028454 | A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth |
| Q39045977 | Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells |
| Q35017911 | Beyond H&E: integration of nucleic acid-based analyses into diagnostic pathology |
| Q38026774 | Blastic leukaemias (AML): a biologist's view |
| Q35803437 | Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia |
| Q91991154 | Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer |
| Q64897624 | Detection of KIT mutations in core binding factor acute myeloid leukemia. |
| Q92847577 | Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia |
| Q42180765 | Expression of c-Kit and PDGFRα in epithelial ovarian tumors and tumor stroma |
| Q26995624 | Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms |
| Q33717707 | GAS6 expression identifies high-risk adult AML patients: potential implications for therapy |
| Q34924515 | High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow |
| Q36682854 | Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target |
| Q39468881 | Kit transduced signals counteract erythroid maturation by MAPK-dependent modulation of erythropoietin signaling and apoptosis induction in mouse fetal liver |
| Q35134457 | Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity |
| Q37973135 | New agents for acute myeloid leukemia: is it time for targeted therapies? |
| Q91936391 | Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia |
| Q50098015 | Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. |
| Q39410783 | Protein kinase inhibitors as therapeutic drugs in AML: advances and challenges. |
| Q39438493 | Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation |
| Q36646486 | Redox control of leukemia: from molecular mechanisms to therapeutic opportunities |
| Q90284727 | Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia |
| Q92128519 | Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How? |
| Q104495182 | Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy |
| Q58581282 | The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51 |
| Q98613708 | The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer |
| Q54273037 | The detection of KIT mutations in acute myeloid leukemia. |
| Q39302268 | The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia |
| Q42327796 | The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm. |
Search more.